Nanobiotix Revenue and Competitors

Paris, France

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Nanobiotix's estimated annual revenue is currently $2.4M per year.(i)
  • Nanobiotix's estimated revenue per employee is $16,879
  • Nanobiotix's current valuation is $328.2M. (January 2022)

Employee Data

  • Nanobiotix has 141 Employees.(i)
  • Nanobiotix grew their employee count by 8% last year.

Nanobiotix's People

NameTitleEmail/Phone
1
CEO & FounderReveal Email/Phone
2
CEO Nanobiotix USA & EVP Business DevelopmentReveal Email/Phone
3
Chief StaffReveal Email/Phone
4
VP, Strategic Partnership, Qualified PersonReveal Email/Phone
5
Head Corporate Development, Strategy and New VenturesReveal Email/Phone
6
Head TransformationReveal Email/Phone
7
Head HR US & Global Head Talent ManagementReveal Email/Phone
8
VP, Global Head Clinical OperationsReveal Email/Phone
9
VP, Strategic Marketing and Corporate CommunicationReveal Email/Phone
10
VP, Global Head Clinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.2M27N/AN/AN/A
Add Company

What Is Nanobiotix?

Incorporated in 2003, Nanobiotix is a leading, late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell. The Nanobiotix philosophy is one rooted in designing pioneer physical based approaches to bring highly effective and generalized solutions to address high unmet medical needs and challenges. Nanobiotix's novel first-in-class, proprietary lead technology, NBTXR3, aims to expand radiotherapy benefits for millions of cancer patients. Furthermore, Nanobiotix's Immuno-Oncology program has the potential to bring a new dimension to cancer immunotherapies. Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP) and on the Nasdaq Global Select Market (Nasdaq: NBTX). The Company's headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

keywords:N/A

N/A

Total Funding

141

Number of Employees

$2.4M

Revenue (est)

8%

Employee Growth %

$328.2M

Valuation

N/A

Accelerator

Nanobiotix News

2022-04-19 - Nanobiotix presents new preclinical data for its nano ...

This oncology platform from Nanobiotix is based on inorganic crystalline hafnium oxide (HfO2) nanoparticles with a diameter of 50 nanometers.

2022-04-06 - NANOBIOTIX Announces Filing of the 2021 Universal ...

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment...

2022-03-22 - NANOBIOTIX Provides Business Update and Reports Full ...

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$22.5M1418%N/A
#2
$15M141-2%N/A
#3
$20.2M14174%N/A
#4
$38.8M1415%N/A
#5
$41.9M14118%N/A